tetano
Editor, Senior Moderator
Vaccine. 2018 Jun 4. pii: S0264-410X(18)30739-4. doi: 10.1016/j.vaccine.2018.05.075. [Epub ahead of print]
[h=1]Intranasal inoculate of influenza virus vaccine against lethal virus challenge.[/h] Fan X[SUP]1[/SUP], Su Q[SUP]2[/SUP], Qiu F[SUP]3[/SUP], Yi Y[SUP]4[/SUP], Shen L[SUP]5[/SUP], Jia Z[SUP]6[/SUP], Liang P[SUP]7[/SUP], Zou Y[SUP]8[/SUP], Bi S[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccine adjuvants are essential for enhancing immune responses during vaccination. However, only a limited number of safe and effective adjuvants, especially mucosal adjuvants, are available for use in vaccines. The development of a practically applicable mucosal adjuvant is therefore urgently needed. Here, we showed that the non-toxic CTA1-DD adjuvant, which combined the full enzymatic activity of the A1 subunit of cholera toxin (CT) with two immunoglobulin-binding domains of Staphylococcus aureus protein A (SpA), promoted mucosal and systemic humoral and cell-mediated immune responses following intranasal administration with H1N1 split vaccine in mice. We demonstrated that CTA1-DD-adjuvant vaccine provided 100% protection against mortality and greatly reduced morbidity in a mouse model. We also showed that addition of CTA1-DD to the vaccine elicited significantly higher hemagglutination inhibition titers and IgG antibodies in sera than alum adjuvant. Furthermore, CTA1-DD significantly promoted the production of mucosal secretory IgA in lung lavages and vaginal lavages. We also showed that CTA1-DD could be used as a mucosal adjuvant to enhance T cell responses. Our results clearly indicated that CTA1-DD contributed to the elicitation of a protective cell-mediated immune response required for efficacious vaccination against influenza virus, which suggested that this adjuvant could be explored further as a clinically safe mucosal vaccine adjuvant for respiratory diseases and other mucosal diseases.
[h=4]KEYWORDS:[/h] CTA1-DD; H1N1; Influenza vaccine; Mucosal adjuvant
PMID: 29880240 DOI: 10.1016/j.vaccine.2018.05.075
[h=1]Intranasal inoculate of influenza virus vaccine against lethal virus challenge.[/h] Fan X[SUP]1[/SUP], Su Q[SUP]2[/SUP], Qiu F[SUP]3[/SUP], Yi Y[SUP]4[/SUP], Shen L[SUP]5[/SUP], Jia Z[SUP]6[/SUP], Liang P[SUP]7[/SUP], Zou Y[SUP]8[/SUP], Bi S[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccine adjuvants are essential for enhancing immune responses during vaccination. However, only a limited number of safe and effective adjuvants, especially mucosal adjuvants, are available for use in vaccines. The development of a practically applicable mucosal adjuvant is therefore urgently needed. Here, we showed that the non-toxic CTA1-DD adjuvant, which combined the full enzymatic activity of the A1 subunit of cholera toxin (CT) with two immunoglobulin-binding domains of Staphylococcus aureus protein A (SpA), promoted mucosal and systemic humoral and cell-mediated immune responses following intranasal administration with H1N1 split vaccine in mice. We demonstrated that CTA1-DD-adjuvant vaccine provided 100% protection against mortality and greatly reduced morbidity in a mouse model. We also showed that addition of CTA1-DD to the vaccine elicited significantly higher hemagglutination inhibition titers and IgG antibodies in sera than alum adjuvant. Furthermore, CTA1-DD significantly promoted the production of mucosal secretory IgA in lung lavages and vaginal lavages. We also showed that CTA1-DD could be used as a mucosal adjuvant to enhance T cell responses. Our results clearly indicated that CTA1-DD contributed to the elicitation of a protective cell-mediated immune response required for efficacious vaccination against influenza virus, which suggested that this adjuvant could be explored further as a clinically safe mucosal vaccine adjuvant for respiratory diseases and other mucosal diseases.
[h=4]KEYWORDS:[/h] CTA1-DD; H1N1; Influenza vaccine; Mucosal adjuvant
PMID: 29880240 DOI: 10.1016/j.vaccine.2018.05.075